Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790819332
CMS profile
1126262
Location
GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$558.49

34 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $558.49 34

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH SHARMA

NPI 1790819332 · CMS profile ID 1126262

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790819332?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790819332?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790819332?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1790819332?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

34 matching records · $558.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 34 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–34 of 34.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $21.0112/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908059913 CMS
EMD Serono, Inc. $14.0812/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027147355 CMS
Genentech USA, Inc. $16.5912/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950721331 CMS
EMD Serono, Inc. $14.5112/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941577611 CMS
Bayer HealthCare Pharmaceuticals Inc. $11.7512/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929813261 CMS
PFIZER INC. $15.4711/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949468749 CMS
Incyte Corporation $15.2910/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032067 CMS
AstraZeneca Pharmaceuticals LP $22.7510/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915728863 CMS
Genentech USA, Inc. $2.2609/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950760802 CMS
Genentech USA, Inc. $16.6309/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950760805 CMS
AstraZeneca Pharmaceuticals LP $19.1509/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915322461 CMS
Pharmacyclics LLC, an AbbVie Company $15.5509/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890347701 CMS
Amgen Inc. $16.8108/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939351957 CMS
Seagen Inc. $19.8708/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090187 CMS
PFIZER INC. $15.4008/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949356389 CMS
BeiGene USA, Inc. $19.3508/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940795523 CMS
Incyte Corporation $16.5307/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032053 CMS
Merck Sharp & Dohme LLC $19.1607/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944181779 CMS
Novartis Pharmaceuticals Corporation $12.7506/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894360419 CMS
JAZZ PHARMACEUTICALS INC. $21.1206/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951356999 CMS
Novartis Pharmaceuticals Corporation $21.5606/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894360415 CMS
Pharmacyclics LLC, an AbbVie Company $24.7905/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890347699 CMS
PFIZER INC. $13.0805/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949156859 CMS
ADC Therapeutics America, Inc. $12.0405/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060939933 CMS
Seagen Inc. $13.3904/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090127 CMS
Exelixis Inc. $12.0103/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932462901 CMS
Pharmacyclics LLC, an AbbVie Company $17.9303/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890347697 CMS
Genentech USA, Inc. $2.2103/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950786911 CMS
Genentech USA, Inc. $18.3803/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950786913 CMS
Novartis Pharmaceuticals Corporation $18.0002/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894360411 CMS
Pharmacyclics LLC, an AbbVie Company $23.8902/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890347695 CMS
Incyte Corporation $21.3001/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032023 CMS
Pharmacyclics LLC, an AbbVie Company $15.4001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890347693 CMS
AstraZeneca Pharmaceuticals LP $18.4801/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915840141 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $659.76 21
PY2020 $185.35 5
PY2021 $23.93 1
PY2022 $558.49 34
PY2023 $1,123.71 47
PY2024 $773.90 11
PY2025 $1,855.50 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $373.20 2
PY2025 Principal investigator $4,235,582.65 823
PY2024 Recipient $4,269.33 9
PY2024 Principal investigator $3,811,534.65 643
PY2023 Recipient $3,810.00 6
PY2023 Principal investigator $3,149,687.09 471
PY2022 Principal investigator $3,302,171.04 339
PY2021 Recipient $7,293.02 4
PY2021 Principal investigator $2,076,760.51 208
PY2020 Recipient $7,900.00 2
PY2020 Principal investigator $1,132,655.23 78
PY2019 Principal investigator $1,305,040.24 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

652 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
M21-404 ABBV-400 Ph1 FIH Advanced Solid Tumors No dispute reported 06/30/2026 1100765599
Principal investigator 1 ABBVIE INC. $718.00 12/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
M24-122 ABBV-303 Ph 1b Dose Escalation Expansion No dispute reported 06/30/2026 1100765601
Principal investigator 1 AstraZeneca Pharmaceuticals LP $842.20 12/31/2024 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS OF WESTERN MICHIGAN, PC
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1155804620
Principal investigator 1 PFIZER INC. $2,403.00 12/27/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130970355
Principal investigator 1 PFIZER INC. $1,996.65 12/27/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1130970361
Principal investigator 1 ABBVIE INC. $3,152.25 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762388
Principal investigator 1 ABBVIE INC. $1,544.40 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762390
Principal investigator 1 ABBVIE INC. $2,589.84 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762392
Principal investigator 1 ABBVIE INC. $4,657.50 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762394
Principal investigator 1 ABBVIE INC. $2,351.70 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762396
Principal investigator 1 ABBVIE INC. $4,233.60 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762408
Principal investigator 1 ABBVIE INC. $1,208.25 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762410
Principal investigator 1 ABBVIE INC. $1,544.40 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762412
Principal investigator 1 ABBVIE INC. $2,589.84 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762486
Principal investigator 1 ABBVIE INC. $2,537.87 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762488
Principal investigator 1 ABBVIE INC. $2,934.77 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762490
Principal investigator 1 ABBVIE INC. $2,516.27 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762492
Principal investigator 1 ABBVIE INC. $1,827.90 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762500
Principal investigator 1 ABBVIE INC. $2,351.70 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762502
Principal investigator 1 ABBVIE INC. $2,250.45 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762504
Principal investigator 1 ABBVIE INC. $255.00 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762508
Principal investigator 1 ABBVIE INC. $1,960.20 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762510
Principal investigator 1 ABBVIE INC. $2,589.84 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762512
Principal investigator 1 ABBVIE INC. $4,657.50 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762522
Principal investigator 1 ABBVIE INC. $2,813.27 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762524
Principal investigator 1 ABBVIE INC. $1,544.40 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762526
Principal investigator 1 ABBVIE INC. $1,776.60 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762528
Principal investigator 1 ABBVIE INC. $1,208.25 12/24/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762530
Principal investigator 1 ABBVIE INC. $3,253.50 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762532
Principal investigator 1 ABBVIE INC. $4,233.60 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762534
Principal investigator 1 ABBVIE INC. $4,657.50 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762536
Principal investigator 1 ABBVIE INC. $2,250.45 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762538
Principal investigator 1 ABBVIE INC. $3,354.75 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762540
Principal investigator 1 ABBVIE INC. $4,233.60 12/24/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100762542
Principal investigator 1 PFIZER INC. $975.00 12/23/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130919625
Principal investigator 1 PFIZER INC. $7.50 12/23/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130920075
Principal investigator 1 PFIZER INC. $2,733.75 12/17/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130953716
Principal investigator 1 Genmab U.S., Inc. $15,397.13 12/12/2024 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193551
Principal investigator 1 Merck Sharp & Dohme LLC $124,520.00 12/12/2024 Non-covered Recipient Entity
START Midwest, LLC
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1136441346
Principal investigator 1 PFIZER INC. $5,332.65 12/06/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130970331
Principal investigator 1 PFIZER INC. $4,667.26 12/05/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130970216
Principal investigator 1 PFIZER INC. $13,702.05 12/05/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130970766
Principal investigator 1 PFIZER INC. $33,061.50 12/04/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1130949724
Principal investigator 1 PFIZER INC. $3,226.50 12/04/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130953722
Principal investigator 1 PFIZER INC. $1,996.65 12/04/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1130970220
Principal investigator 1 PFIZER INC. $2,340.00 12/04/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130970772
Principal investigator 1 ABBVIE INC. $2,813.27 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757073
Principal investigator 1 ABBVIE INC. $28,657.80 11/28/2024 Non-covered Recipient Entity
START MIDWEST LL
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1100757075
Principal investigator 1 ABBVIE INC. $1,135.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757077
Principal investigator 1 ABBVIE INC. $1,702.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757083
Principal investigator 1 ABBVIE INC. $2,798.42 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757085
Principal investigator 1 ABBVIE INC. $1,702.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757087
Principal investigator 1 ABBVIE INC. $1,702.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757091
Principal investigator 1 ABBVIE INC. $1,135.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757093
Principal investigator 1 ABBVIE INC. $2,298.92 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757105
Principal investigator 1 ABBVIE INC. $2,589.84 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757107
Principal investigator 1 ABBVIE INC. $2,798.42 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757109
Principal investigator 1 ABBVIE INC. $1,637.55 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757111
Principal investigator 1 ABBVIE INC. $1,135.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757117
Principal investigator 1 ABBVIE INC. $1,135.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757119
Principal investigator 1 ABBVIE INC. $2,813.27 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757121
Principal investigator 1 ABBVIE INC. $1,456.65 11/28/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757123
Principal investigator 1 ABBVIE INC. $2,798.42 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757125
Principal investigator 1 ABBVIE INC. $1,702.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757127
Principal investigator 1 ABBVIE INC. $3,812.27 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757129
Principal investigator 1 ABBVIE INC. $2,366.28 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757131
Principal investigator 1 ABBVIE INC. $2,298.92 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757135
Principal investigator 1 ABBVIE INC. $1,702.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757137
Principal investigator 1 ABBVIE INC. $1,135.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757139
Principal investigator 1 ABBVIE INC. $1,702.35 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757141
Principal investigator 1 ABBVIE INC. $2,366.28 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757149
Principal investigator 1 ABBVIE INC. $2,298.92 11/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100757151
Principal investigator 1 PFIZER INC. $7,836.75 11/27/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1130949899
Principal investigator 1 PFIZER INC. $8,637.50 11/26/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130986777
Principal investigator 1 ABBVIE INC. $2,060.10 11/25/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100756463
Principal investigator 1 MACROGENICS, INC. $700.00 11/25/2024 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1127670066
Principal investigator 1 ABBVIE INC. $1,499.85 11/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100756119
Principal investigator 1 ABBVIE INC. $1,499.85 11/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100756123
Principal investigator 1 ABBVIE INC. $1,135.35 11/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100756125
Principal investigator 1 PFIZER INC. $650.00 11/21/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130919621
Principal investigator 1 ABBVIE INC. $365.85 11/20/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100755947
Principal investigator 1 PFIZER INC. $31,078.00 11/20/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130949730
Principal investigator 1 PFIZER INC. $2,270.70 11/20/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130975072
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $39,245.00 11/19/2024 Non-covered Recipient Entity
Start Midwest
Phase I/IIA CD40xFAP Mono, Doublet, Triplet - A Phase 1/1b First- in -Human Trial of BMS-986484 as Monotherapy and in Combination Therapies in Participants with Advanced Solid Malignancies No dispute reported 06/30/2026 1123479978
Principal investigator 1 PFIZER INC. $59,240.76 11/19/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130919629
Principal investigator 1 PFIZER INC. $7.50 11/19/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130920071
Principal investigator 1 Stemline Therapeutics Inc. $143.64 11/08/2024 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1142965328
Principal investigator 1 PFIZER INC. $35,044.00 11/05/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE No dispute reported 06/30/2026 1130949736
Principal investigator 1 PFIZER INC. $1,439.10 11/05/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130975263
Principal investigator 1 PFIZER INC. $1,996.65 11/05/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1130987412
Principal investigator 1 ABBVIE INC. $3,711.15 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751441
Principal investigator 1 ABBVIE INC. $3,152.25 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751443
Principal investigator 1 ABBVIE INC. $1,208.25 11/01/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751445
Principal investigator 1 ABBVIE INC. $3,711.15 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751449
Principal investigator 1 ABBVIE INC. $3,152.25 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751451
Principal investigator 1 ABBVIE INC. $3,152.25 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751453
Principal investigator 1 ABBVIE INC. $3,253.50 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751455
Principal investigator 1 ABBVIE INC. $3,152.25 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751457
Principal investigator 1 ABBVIE INC. $3,711.15 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751459
Principal investigator 1 ABBVIE INC. $3,152.25 11/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751461
Principal investigator 1 ABBVIE INC. $364.50 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751021
Principal investigator 1 ABBVIE INC. $1,208.25 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751023
Principal investigator 1 ABBVIE INC. $1,034.10 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751025
Principal investigator 1 ABBVIE INC. $2,267.19 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751035
Principal investigator 1 ABBVIE INC. $1,135.35 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751045
Principal investigator 1 ABBVIE INC. $2,366.28 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751047
Principal investigator 1 ABBVIE INC. $2,813.27 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751049
Principal investigator 1 ABBVIE INC. $1,034.10 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751051
Principal investigator 1 ABBVIE INC. $2,610.77 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751079
Principal investigator 1 ABBVIE INC. $1,702.35 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751081
Principal investigator 1 ABBVIE INC. $1,907.01 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751083
Principal investigator 1 ABBVIE INC. $1,681.97 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751085
Principal investigator 1 ABBVIE INC. $2,813.27 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751095
Principal investigator 1 ABBVIE INC. $2,460.78 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751097
Principal investigator 1 ABBVIE INC. $807.30 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100751101
Principal investigator 1 ABBVIE INC. $2,267.19 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751111
Principal investigator 1 ABBVIE INC. $2,798.42 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751113
Principal investigator 1 ABBVIE INC. $1,034.10 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751117
Principal investigator 1 ABBVIE INC. $1,135.35 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751119
Principal investigator 1 ABBVIE INC. $1,702.35 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751121
Principal investigator 1 ABBVIE INC. $2,813.27 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751123
Principal investigator 1 ABBVIE INC. $1,827.90 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751125
Principal investigator 1 ABBVIE INC. $2,042.55 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751127
Principal investigator 1 ABBVIE INC. $2,298.92 10/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100751129
Principal investigator 1 MACROGENICS, INC. $2,786.86 10/28/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669998
Principal investigator 1 PFIZER INC. $650.00 10/28/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130920024
Principal investigator 1 PFIZER INC. $15.00 10/28/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130920067
Principal investigator 1 ABBVIE INC. $3,000.00 10/25/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100750478
Principal investigator 1 PFIZER INC. $8,050.82 10/25/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130993443
Principal investigator 1 PFIZER INC. $2,177.55 10/24/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1130992838
Principal investigator 1 PFIZER INC. $50,694.46 10/24/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130994662
Principal investigator 1 Merck Sharp & Dohme LLC $49,700.00 10/22/2024 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics START Midwest
Phase I Study of Pembrolizumab in Patients with Human Immunodeficiency Virus HIV and Relapsed,Refractory or Disseminated Malignant Neoplasm No dispute reported 06/30/2026 1136411405
Principal investigator 1 PFIZER INC. $4,541.40 10/22/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130999288
Principal investigator 1 PFIZER INC. $4,642.42 10/16/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130992832
Principal investigator 1 Stemline Therapeutics Inc. $94.69 10/14/2024 Non-covered Recipient Entity
START MIDWEST, LLC
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1142965324
Principal investigator 1 PFIZER INC. $92.48 10/05/2024 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1130992844
Principal investigator 1 PFIZER INC. $202.50 10/05/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130993436
Principal investigator 1 Genmab U.S., Inc. $3,924.48 10/04/2024 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193555
Principal investigator 1 ABBVIE INC. $69,704.55 10/02/2024 Non-covered Recipient Entity
START MIDWEST LL
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1100745096
Principal investigator 1 ABBVIE INC. $3,253.50 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744746
Principal investigator 1 ABBVIE INC. $2,060.10 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744748
Principal investigator 1 ABBVIE INC. $3,354.75 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744750
Principal investigator 1 ABBVIE INC. $3,253.50 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744756
Principal investigator 1 ABBVIE INC. $2,351.70 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744770
Principal investigator 1 ABBVIE INC. $3,152.25 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744772
Principal investigator 1 ABBVIE INC. $3,152.25 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744774
Principal investigator 1 ABBVIE INC. $3,152.25 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744776
Principal investigator 1 ABBVIE INC. $3,253.50 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744778
Principal investigator 1 ABBVIE INC. $3,354.75 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744796
Principal investigator 1 ABBVIE INC. $1,776.60 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744798
Principal investigator 1 ABBVIE INC. $3,152.25 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744804
Principal investigator 1 ABBVIE INC. $3,152.25 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744806
Principal investigator 1 ABBVIE INC. $4,233.60 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744808
Principal investigator 1 ABBVIE INC. $4,657.50 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744810
Principal investigator 1 ABBVIE INC. $3,152.25 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744816
Principal investigator 1 ABBVIE INC. $1,544.40 09/27/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744818
Principal investigator 1 ABBVIE INC. $2,089.53 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744106
Principal investigator 1 ABBVIE INC. $4,749.17 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744108
Principal investigator 1 ABBVIE INC. $1,135.35 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744126
Principal investigator 1 ABBVIE INC. $1,034.10 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744132
Principal investigator 1 ABBVIE INC. $2,001.51 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744138
Principal investigator 1 ABBVIE INC. $2,611.44 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744140
Principal investigator 1 ABBVIE INC. $2,813.27 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744146
Principal investigator 1 ABBVIE INC. $2,267.19 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744148
Principal investigator 1 ABBVIE INC. $1,135.35 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744150
Principal investigator 1 ABBVIE INC. $1,907.01 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744152
Principal investigator 1 ABBVIE INC. $1,907.01 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744154
Principal investigator 1 ABBVIE INC. $2,106.54 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744156
Principal investigator 1 ABBVIE INC. $1,907.01 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744158
Principal investigator 1 ABBVIE INC. $2,001.51 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744160
Principal investigator 1 ABBVIE INC. $2,611.44 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744162
Principal investigator 1 ABBVIE INC. $3,751.52 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744164
Principal investigator 1 ABBVIE INC. $2,001.51 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744166
Principal investigator 1 ABBVIE INC. $4,180.14 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744168
Principal investigator 1 ABBVIE INC. $2,107.35 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744172
Principal investigator 1 ABBVIE INC. $1,611.63 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744180
Principal investigator 1 ABBVIE INC. $2,267.19 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744182
Principal investigator 1 ABBVIE INC. $1,842.21 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744186
Principal investigator 1 ABBVIE INC. $1,611.63 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744196
Principal investigator 1 ABBVIE INC. $1,611.63 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744198
Principal investigator 1 ABBVIE INC. $2,813.27 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744200
Principal investigator 1 ABBVIE INC. $1,135.35 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744202
Principal investigator 1 ABBVIE INC. $1,576.26 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744204
Principal investigator 1 ABBVIE INC. $2,611.44 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744206
Principal investigator 1 ABBVIE INC. $2,001.51 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744216
Principal investigator 1 ABBVIE INC. $2,813.27 09/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100744218
Principal investigator 1 PFIZER INC. $7,134.75 09/25/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131012394
Principal investigator 1 PFIZER INC. $1,996.65 09/25/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1131017328
Principal investigator 1 PFIZER INC. $3,393.13 09/25/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131017523
Principal investigator 1 PFIZER INC. $9,309.68 09/25/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131017529
Principal investigator 1 PFIZER INC. $325.00 09/16/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130957459
Recipient PFIZER INC. $940.00 09/13/2024 Covered Recipient Physician NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130903729
Principal investigator 1 PFIZER INC. $4,642.42 09/07/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131016921
Principal investigator 1 PFIZER INC. $3,160.00 09/04/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 1131011310
Principal investigator 1 PFIZER INC. $15.00 09/03/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130957414
Principal investigator 1 PFIZER INC. $650.00 09/03/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130957453
Principal investigator 1 ABBVIE INC. $4,180.14 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738046
Principal investigator 1 ABBVIE INC. $1,034.10 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738114
Principal investigator 1 ABBVIE INC. $2,611.44 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738122
Principal investigator 1 ABBVIE INC. $1,552.50 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738140
Principal investigator 1 ABBVIE INC. $1,196.10 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738142
Principal investigator 1 ABBVIE INC. $2,718.77 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738144
Principal investigator 1 ABBVIE INC. $2,267.19 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738146
Principal investigator 1 ABBVIE INC. $1,196.10 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738148
Principal investigator 1 ABBVIE INC. $1,540.35 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738164
Principal investigator 1 ABBVIE INC. $3,002.27 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738166
Principal investigator 1 ABBVIE INC. $4,180.14 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738168
Principal investigator 1 ABBVIE INC. $5,817.15 08/29/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738170
Principal investigator 1 ABBVIE INC. $1,611.63 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738188
Principal investigator 1 ABBVIE INC. $1,135.35 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738190
Principal investigator 1 ABBVIE INC. $1,472.85 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738192
Principal investigator 1 ABBVIE INC. $2,813.27 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738194
Principal investigator 1 ABBVIE INC. $4,180.14 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738222
Principal investigator 1 ABBVIE INC. $365.85 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738224
Principal investigator 1 ABBVIE INC. $1,912.68 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738226
Principal investigator 1 ABBVIE INC. $2,157.84 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738228
Principal investigator 1 ABBVIE INC. $2,327.94 08/29/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100738230
Principal investigator 1 PFIZER INC. $70,442.78 08/28/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131034376
Principal investigator 1 PFIZER INC. $33,758.66 08/23/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131033404
Principal investigator 1 PFIZER INC. $13,952.10 08/23/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131033812
Principal investigator 1 MACROGENICS, INC. $135.00 08/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669694
Principal investigator 1 PFIZER INC. $2,177.55 08/22/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1131033806
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736876
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736892
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736894
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736896
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736908
Principal investigator 1 ABBVIE INC. $216.00 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736916
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736918
Principal investigator 1 ABBVIE INC. $216.00 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736920
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736924
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736926
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736928
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736930
Principal investigator 1 ABBVIE INC. $67.50 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736946
Principal investigator 1 ABBVIE INC. $237.60 08/20/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100736948
Principal investigator 1 PFIZER INC. $4,410.00 08/07/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 1131034042
Principal investigator 1 PFIZER INC. $19,419.79 08/06/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131034383
Principal investigator 1 PFIZER INC. $9,284.84 08/03/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131033582
Principal investigator 1 PFIZER INC. $398,665.29 08/02/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131033799
Principal investigator 1 ABBVIE INC. $4,660.20 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731540
Principal investigator 1 ABBVIE INC. $364.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731542
Principal investigator 1 ABBVIE INC. $2,611.44 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731544
Principal investigator 1 ABBVIE INC. $1,456.65 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731568
Principal investigator 1 ABBVIE INC. $3,711.15 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731570
Principal investigator 1 ABBVIE INC. $2,060.10 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731572
Principal investigator 1 ABBVIE INC. $1,907.01 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731574
Principal investigator 1 ABBVIE INC. $3,152.25 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731576
Principal investigator 1 ABBVIE INC. $1,485.00 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731650
Principal investigator 1 ABBVIE INC. $1,456.65 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731652
Principal investigator 1 ABBVIE INC. $2,351.70 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731654
Principal investigator 1 ABBVIE INC. $3,354.75 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731656
Principal investigator 1 ABBVIE INC. $950.40 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731658
Principal investigator 1 ABBVIE INC. $2,001.51 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731660
Principal investigator 1 ABBVIE INC. $2,813.27 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731662
Principal investigator 1 ABBVIE INC. $1,776.60 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731702
Principal investigator 1 ABBVIE INC. $3,354.75 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731704
Principal investigator 1 ABBVIE INC. $3,354.75 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731706
Principal investigator 1 ABBVIE INC. $3,711.15 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731708
Principal investigator 1 ABBVIE INC. $1,611.63 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731710
Principal investigator 1 ABBVIE INC. $4,233.60 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731746
Principal investigator 1 ABBVIE INC. $3,152.25 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731748
Principal investigator 1 ABBVIE INC. $1,456.65 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731750
Principal investigator 1 ABBVIE INC. $364.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731752
Principal investigator 1 ABBVIE INC. $3,173.85 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731754
Principal investigator 1 ABBVIE INC. $1,968.03 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731786
Principal investigator 1 ABBVIE INC. $500.85 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731788
Principal investigator 1 ABBVIE INC. $3,354.75 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731790
Principal investigator 1 ABBVIE INC. $3,152.25 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731792
Principal investigator 1 ABBVIE INC. $1,456.65 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731794
Principal investigator 1 ABBVIE INC. $2,351.70 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731796
Principal investigator 1 ABBVIE INC. $3,354.75 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731798
Principal investigator 1 ABBVIE INC. $1,456.65 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731800
Principal investigator 1 ABBVIE INC. $1,456.65 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731856
Principal investigator 1 ABBVIE INC. $1,544.40 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731872
Principal investigator 1 ABBVIE INC. $3,152.25 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731874
Principal investigator 1 ABBVIE INC. $5,709.15 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731876
Principal investigator 1 ABBVIE INC. $3,152.25 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731878
Principal investigator 1 ABBVIE INC. $978.75 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731880
Principal investigator 1 ABBVIE INC. $2,717.55 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731882
Principal investigator 1 ABBVIE INC. $2,034.45 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731884
Principal investigator 1 ABBVIE INC. $2,250.45 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731910
Principal investigator 1 ABBVIE INC. $3,775.95 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100731912
Principal investigator 1 ABBVIE INC. $364.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731914
Principal investigator 1 ABBVIE INC. $500.85 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731916
Principal investigator 1 ABBVIE INC. $4,018.14 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731918
Principal investigator 1 ABBVIE INC. $3,253.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731964
Principal investigator 1 ABBVIE INC. $1,544.40 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731966
Principal investigator 1 ABBVIE INC. $3,253.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731968
Principal investigator 1 ABBVIE INC. $3,253.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731970
Principal investigator 1 ABBVIE INC. $4,233.60 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731972
Principal investigator 1 ABBVIE INC. $4,657.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100731974
Principal investigator 1 ABBVIE INC. $2,250.45 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732014
Principal investigator 1 ABBVIE INC. $3,253.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732016
Principal investigator 1 ABBVIE INC. $3,354.75 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732018
Principal investigator 1 ABBVIE INC. $4,657.50 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732020
Principal investigator 1 ABBVIE INC. $1,776.60 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732022
Principal investigator 1 ABBVIE INC. $2,351.70 07/31/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732024
Principal investigator 1 ABBVIE INC. $1,113.75 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732068
Principal investigator 1 ABBVIE INC. $1,135.35 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732070
Principal investigator 1 ABBVIE INC. $2,408.27 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732072
Principal investigator 1 ABBVIE INC. $2,469.96 07/31/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100732074
Principal investigator 1 ABBVIE INC. $2,342.25 07/25/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100730872
Principal investigator 1 ABBVIE INC. $2,227.50 07/25/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100730874
Principal investigator 1 ABBVIE INC. $2,436.75 07/25/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100730876
Principal investigator 1 PFIZER INC. $51,463.35 07/24/2024 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1131043351
Principal investigator 1 MACROGENICS, INC. $4,801.87 07/18/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669574
Principal investigator 1 MACROGENICS, INC. $2,043.35 07/18/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669576
Principal investigator 1 MACROGENICS, INC. $3,371.53 07/18/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669578
Principal investigator 1 PFIZER INC. $2,367.90 07/11/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1131043344
Principal investigator 1 PFIZER INC. $7.50 07/09/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130956762
Principal investigator 1 PFIZER INC. $650.00 07/09/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130956768
Principal investigator 1 PFIZER INC. $975.00 07/09/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1130957465
Principal investigator 1 ABBVIE INC. $765.00 07/04/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100726742
Principal investigator 1 ABBVIE INC. $126.00 07/04/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100726746
Principal investigator 1 ABBVIE INC. $504.00 07/04/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100726750
Principal investigator 1 ABBVIE INC. $510.00 07/03/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100725492
Principal investigator 1 ABBVIE INC. $6,000.00 07/03/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100725586
Principal investigator 1 ABBVIE INC. $1,020.00 07/03/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100725694
Principal investigator 1 ABBVIE INC. $1,058.40 07/01/2024 Non-covered Recipient Entity
START MIDWEST
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100725050
Principal investigator 1 ABBVIE INC. $2,062.53 06/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724632
Principal investigator 1 ABBVIE INC. $2,847.20 06/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724634
Principal investigator 1 ABBVIE INC. $4,180.14 06/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724680
Principal investigator 1 ABBVIE INC. $1,691.28 06/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724698
Principal investigator 1 ABBVIE INC. $2,941.52 06/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724700
Principal investigator 1 ABBVIE INC. $364.50 06/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724706
Principal investigator 1 ABBVIE INC. $1,196.10 06/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724708
Principal investigator 1 ABBVIE INC. $2,813.27 06/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724710
Principal investigator 1 PFIZER INC. $19,223.31 06/26/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131059717
Principal investigator 1 PFIZER INC. $3,005.00 06/26/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 1131059723
Principal investigator 1 PFIZER INC. $115,767.90 06/26/2024 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1131066657
Principal investigator 1 PFIZER INC. $830.85 06/26/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1131067277
Principal investigator 1 ABBVIE INC. $4,064.61 06/20/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724092
Principal investigator 1 ABBVIE INC. $270.00 06/19/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100723996
Principal investigator 1 ABBVIE INC. $4,876.20 06/19/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100723998
Principal investigator 1 ABBVIE INC. $270.00 06/19/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724000
Principal investigator 1 ABBVIE INC. $1,788.75 06/19/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724002
Principal investigator 1 ABBVIE INC. $4,876.20 06/19/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724004
Principal investigator 1 ABBVIE INC. $1,788.75 06/19/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724006
Principal investigator 1 ABBVIE INC. $822.84 06/19/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100724014
Principal investigator 1 Merck Sharp & Dohme LLC $56,800.00 06/18/2024 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics START Midwest
A Phase 1,1b Dose Escalation,Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1136397349
Principal investigator 1 PFIZER INC. $2,177.55 06/14/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1131069861
Principal investigator 1 ABBVIE INC. $1,211.96 06/12/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100723294
Principal investigator 1 ABBVIE INC. $1,409.10 06/12/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100723296
Principal investigator 1 ABBVIE INC. $2,818.21 06/12/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100723298
Principal investigator 1 PFIZER INC. $55.00 06/04/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 1131059672
Principal investigator 1 ABBVIE INC. $1,776.60 06/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720330
Principal investigator 1 ABBVIE INC. $2,060.10 06/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720332
Principal investigator 1 ABBVIE INC. $2,060.10 06/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720338
Principal investigator 1 ABBVIE INC. $3,354.75 06/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720340
Principal investigator 1 ABBVIE INC. $1,776.60 06/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720342
Principal investigator 1 ABBVIE INC. $3,152.25 06/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720352
Principal investigator 1 PFIZER INC. $975.00 06/03/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131016151
Principal investigator 1 PFIZER INC. $12,979.84 06/01/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131059729
Principal investigator 1 PFIZER INC. $16,170.30 06/01/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1131067939
Recipient ABBVIE INC. $87.61 05/31/2024 Covered Recipient Physician Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment No dispute reported 06/30/2026 1100681599
Recipient ABBVIE INC. $41.72 05/31/2024 Covered Recipient Physician A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1100681601
Principal investigator 1 ABBVIE INC. $2,813.27 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720034
Principal investigator 1 ABBVIE INC. $4,371.17 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720036
Principal investigator 1 ABBVIE INC. $2,537.87 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720038
Principal investigator 1 ABBVIE INC. $364.50 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720040
Principal investigator 1 ABBVIE INC. $2,718.77 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720048
Principal investigator 1 ABBVIE INC. $2,598.62 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720050
Principal investigator 1 ABBVIE INC. $364.50 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720052
Principal investigator 1 ABBVIE INC. $364.50 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720078
Principal investigator 1 ABBVIE INC. $4,575.18 05/30/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100720094
Principal investigator 1 PFIZER INC. $650.00 05/29/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131015781
Principal investigator 1 PFIZER INC. $7.50 05/29/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131016362
Principal investigator 1 ABBVIE INC. $12,714.37 05/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100719700
Principal investigator 1 PFIZER INC. $5,488.07 05/24/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076329
Principal investigator 1 ABBVIE INC. $4,064.61 05/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100719300
Principal investigator 1 ABBVIE INC. $5,817.15 05/20/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100719044
Principal investigator 1 ABBVIE INC. $5,817.15 05/20/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100719046
Principal investigator 1 ABBVIE INC. $250.00 05/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100718678
Principal investigator 1 ABBVIE INC. $250.00 05/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100718680
Recipient PFIZER INC. $940.00 05/16/2024 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130904059
Principal investigator 1 PFIZER INC. $2,407.00 05/15/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 1131075737
Principal investigator 1 PFIZER INC. $9,367.19 05/14/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076417
Principal investigator 1 MACROGENICS, INC. $1,784.52 05/13/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669240
Principal investigator 1 MACROGENICS, INC. $759.37 05/13/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669242
Principal investigator 1 MACROGENICS, INC. $1,252.96 05/13/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669244
Recipient PFIZER INC. $330.00 05/07/2024 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130904055
Recipient PFIZER INC. $330.00 05/06/2024 Covered Recipient Physician COFETUZUMAB PELIDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130904051
Principal investigator 1 PFIZER INC. $975.00 05/06/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131015787
Principal investigator 1 PFIZER INC. $12,269.00 05/04/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 1131076411
Principal investigator 1 PFIZER INC. $6,279.40 05/04/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131083152
Principal investigator 1 Exelixis Inc. $7,429.00 05/03/2024 Non-covered Recipient Entity
START Midwest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632128
Principal investigator 1 Exelixis Inc. $2,322.00 05/03/2024 Non-covered Recipient Entity
START Midwest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632130
Principal investigator 1 MACROGENICS, INC. $2,751.62 05/01/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669206
Principal investigator 1 MACROGENICS, INC. $1,170.90 05/01/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669208
Principal investigator 1 MACROGENICS, INC. $1,931.99 05/01/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669210
Principal investigator 1 ABBVIE INC. $17,126.10 04/30/2024 Non-covered Recipient Entity
START MIDWEST LL
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1100715306
Principal investigator 1 ABBVIE INC. $220.00 04/30/2024 Non-covered Recipient Entity
START MIDWEST LL
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1100715308
Principal investigator 1 PFIZER INC. $1,095.17 04/27/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076213
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715148
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715150
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715152
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715154
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715158
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715160
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715162
Principal investigator 1 ABBVIE INC. $1,472.85 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715164
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715168
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715196
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715198
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715200
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715226
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715228
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715230
Principal investigator 1 ABBVIE INC. $364.50 04/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100715232
Principal investigator 1 PFIZER INC. $4,938.49 04/26/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076113
Principal investigator 1 PFIZER INC. $28,245.52 04/26/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076406
Principal investigator 1 PFIZER INC. $40,055.00 04/26/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076694
Principal investigator 1 Merck Sharp & Dohme LLC $42,600.00 04/25/2024 Non-covered Recipient Entity
START MidWest
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1136444965
Principal investigator 1 PFIZER INC. $39,502.32 04/25/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131088605
Principal investigator 1 MACROGENICS, INC. $11,460.18 04/23/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669116
Principal investigator 1 MACROGENICS, INC. $4,876.67 04/23/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669118
Principal investigator 1 MACROGENICS, INC. $8,046.51 04/23/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127669120
Recipient PFIZER INC. $940.00 04/23/2024 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130903725
Principal investigator 1 PFIZER INC. $7.50 04/18/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131016368
Principal investigator 1 PFIZER INC. $975.00 04/18/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131017571
Principal investigator 1 PFIZER INC. $1,190.00 04/16/2024 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1131089993
Principal investigator 1 Genmab U.S., Inc. $9,230.00 04/11/2024 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193543
Principal investigator 1 Merck Sharp & Dohme LLC $71,000.00 04/11/2024 Non-covered Recipient Entity
START MidWest
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1136441237
Principal investigator 1 PFIZER INC. $15.00 04/11/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131016158
Principal investigator 1 PFIZER INC. $325.00 04/11/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131016163
Principal investigator 1 Exelixis Inc. $2,255.00 04/10/2024 Non-covered Recipient Entity
START Midwest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138632126
Principal investigator 1 PFIZER INC. $45,448.69 04/10/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076798
Principal investigator 1 PFIZER INC. $18,157.50 04/09/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1131088475
Principal investigator 1 PFIZER INC. $13,927.26 04/05/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076740
Principal investigator 1 PFIZER INC. $975.00 04/04/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131016927
Principal investigator 1 ABBVIE INC. $704.20 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710644
Principal investigator 1 ABBVIE INC. $3,355.00 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710646
Principal investigator 1 ABBVIE INC. $7,668.00 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710648
Principal investigator 1 ABBVIE INC. $1,550.00 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710652
Principal investigator 1 ABBVIE INC. $1,000.00 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710654
Principal investigator 1 ABBVIE INC. $3,000.00 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710656
Principal investigator 1 ABBVIE INC. $1,834.00 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710658
Principal investigator 1 ABBVIE INC. $1,000.00 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710660
Principal investigator 1 ABBVIE INC. $13,000.00 04/03/2024 Non-covered Recipient Entity
START MIDWEST LLC
A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1100710664
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710442
Principal investigator 1 ABBVIE INC. $222.75 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710444
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710446
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710448
Principal investigator 1 ABBVIE INC. $500.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710454
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710456
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710466
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710470
Principal investigator 1 ABBVIE INC. $100.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710472
Principal investigator 1 ABBVIE INC. $100.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710474
Principal investigator 1 ABBVIE INC. $100.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710476
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710478
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710480
Principal investigator 1 ABBVIE INC. $250.70 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710482
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710484
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710486
Principal investigator 1 ABBVIE INC. $125.35 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710488
Principal investigator 1 ABBVIE INC. $182.85 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710490
Principal investigator 1 ABBVIE INC. $850.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710496
Principal investigator 1 ABBVIE INC. $1,500.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710498
Principal investigator 1 ABBVIE INC. $1,500.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710500
Principal investigator 1 ABBVIE INC. $2,100.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710502
Principal investigator 1 ABBVIE INC. $2,350.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710504
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710506
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710508
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710510
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710512
Principal investigator 1 ABBVIE INC. $1,613.83 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710514
Principal investigator 1 ABBVIE INC. $500.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710516
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710520
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710526
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710528
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710534
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710536
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710538
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710540
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710542
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710544
Principal investigator 1 ABBVIE INC. $222.75 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710546
Principal investigator 1 ABBVIE INC. $125.35 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710548
Principal investigator 1 ABBVIE INC. $222.75 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710552
Principal investigator 1 ABBVIE INC. $222.75 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710554
Principal investigator 1 ABBVIE INC. $222.75 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710556
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710558
Principal investigator 1 ABBVIE INC. $94.50 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710560
Principal investigator 1 ABBVIE INC. $125.35 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710562
Principal investigator 1 ABBVIE INC. $125.35 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710564
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710566
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710568
Principal investigator 1 ABBVIE INC. $250.00 04/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100710570
Principal investigator 1 ABBVIE INC. $3,500.00 03/31/2024 Non-covered Recipient Entity
START MIDWEST LL
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1100710314
Principal investigator 1 ABBVIE INC. $40,096.00 03/31/2024 Non-covered Recipient Entity
START MIDWEST LL
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1100710316
Principal investigator 1 ABBVIE INC. $3,690.00 03/31/2024 Non-covered Recipient Entity
START MIDWEST LL
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1100710318
Principal investigator 1 PFIZER INC. $1,382.40 03/29/2024 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1131104443
Principal investigator 1 ABBVIE INC. $3,354.75 03/27/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709872
Principal investigator 1 PFIZER INC. $234,291.26 03/27/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131104278
Principal investigator 1 PFIZER INC. $40,055.00 03/27/2024 Non-covered Recipient Entity
START Midwest LLC
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER No dispute reported 06/30/2026 1131104319
Principal investigator 1 ABBVIE INC. $2,847.20 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709316
Principal investigator 1 ABBVIE INC. $1,840.00 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709318
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709320
Principal investigator 1 ABBVIE INC. $1,113.75 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709322
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709324
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709326
Principal investigator 1 ABBVIE INC. $2,537.87 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709330
Principal investigator 1 ABBVIE INC. $2,934.77 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709332
Principal investigator 1 ABBVIE INC. $2,537.87 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709334
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709342
Principal investigator 1 ABBVIE INC. $2,374.52 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709344
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709346
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709348
Principal investigator 1 ABBVIE INC. $1,113.75 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709350
Principal investigator 1 ABBVIE INC. $1,196.10 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709352
Principal investigator 1 ABBVIE INC. $1,196.10 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709354
Principal investigator 1 ABBVIE INC. $3,002.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709360
Principal investigator 1 ABBVIE INC. $500.85 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709362
Principal investigator 1 ABBVIE INC. $500.85 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709388
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709390
Principal investigator 1 ABBVIE INC. $1,113.75 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709392
Principal investigator 1 ABBVIE INC. $500.85 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709394
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709396
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709398
Principal investigator 1 ABBVIE INC. $1,196.10 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709402
Principal investigator 1 ABBVIE INC. $1,691.28 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709408
Principal investigator 1 ABBVIE INC. $2,062.53 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709410
Principal investigator 1 ABBVIE INC. $2,968.52 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709412
Principal investigator 1 ABBVIE INC. $2,408.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709414
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709416
Principal investigator 1 ABBVIE INC. $2,718.77 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709418
Principal investigator 1 ABBVIE INC. $4,371.17 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709420
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709422
Principal investigator 1 ABBVIE INC. $2,537.87 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709424
Principal investigator 1 ABBVIE INC. $2,062.53 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709432
Principal investigator 1 ABBVIE INC. $1,968.03 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709434
Principal investigator 1 ABBVIE INC. $1,579.50 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709436
Principal investigator 1 ABBVIE INC. $2,718.77 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709438
Principal investigator 1 ABBVIE INC. $1,034.10 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709440
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709442
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709444
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709446
Principal investigator 1 ABBVIE INC. $2,062.53 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709448
Principal investigator 1 ABBVIE INC. $2,062.53 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709450
Principal investigator 1 ABBVIE INC. $2,062.53 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709452
Principal investigator 1 ABBVIE INC. $2,537.87 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709454
Principal investigator 1 ABBVIE INC. $364.50 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709474
Principal investigator 1 ABBVIE INC. $2,934.77 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709490
Principal investigator 1 ABBVIE INC. $2,062.53 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709492
Principal investigator 1 ABBVIE INC. $3,029.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709494
Principal investigator 1 ABBVIE INC. $2,062.53 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709496
Principal investigator 1 ABBVIE INC. $1,034.10 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709498
Principal investigator 1 ABBVIE INC. $2,062.53 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709526
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709528
Principal investigator 1 ABBVIE INC. $2,313.77 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709530
Principal investigator 1 ABBVIE INC. $2,537.87 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709532
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709556
Principal investigator 1 ABBVIE INC. $1,552.50 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709558
Principal investigator 1 ABBVIE INC. $4,371.17 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709560
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709562
Principal investigator 1 ABBVIE INC. $500.85 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709564
Principal investigator 1 ABBVIE INC. $2,537.87 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709576
Principal investigator 1 ABBVIE INC. $364.50 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709594
Principal investigator 1 ABBVIE INC. $2,847.20 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709604
Principal investigator 1 ABBVIE INC. $1,113.75 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709606
Principal investigator 1 ABBVIE INC. $2,529.77 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709608
Principal investigator 1 ABBVIE INC. $1,579.50 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709610
Principal investigator 1 ABBVIE INC. $2,313.77 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709612
Principal investigator 1 ABBVIE INC. $1,968.03 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709630
Principal investigator 1 ABBVIE INC. $2,408.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709632
Principal investigator 1 ABBVIE INC. $2,941.52 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709634
Principal investigator 1 ABBVIE INC. $2,408.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709636
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709638
Principal investigator 1 ABBVIE INC. $2,813.27 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709640
Principal investigator 1 ABBVIE INC. $500.85 03/22/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709642
Principal investigator 1 ABBVIE INC. $2,250.45 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708883
Principal investigator 1 ABBVIE INC. $4,657.50 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708891
Principal investigator 1 ABBVIE INC. $3,152.25 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708893
Principal investigator 1 ABBVIE INC. $1,544.40 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708903
Principal investigator 1 ABBVIE INC. $2,250.45 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708905
Principal investigator 1 ABBVIE INC. $2,060.10 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708913
Principal investigator 1 ABBVIE INC. $1,544.40 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709165
Principal investigator 1 ABBVIE INC. $4,233.60 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709167
Principal investigator 1 ABBVIE INC. $3,152.25 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709179
Principal investigator 1 ABBVIE INC. $4,657.50 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709181
Principal investigator 1 ABBVIE INC. $2,351.70 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709191
Principal investigator 1 ABBVIE INC. $1,544.40 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709193
Principal investigator 1 ABBVIE INC. $4,657.50 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709257
Principal investigator 1 ABBVIE INC. $2,060.10 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709264
Principal investigator 1 ABBVIE INC. $3,354.75 03/21/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100709266
Principal investigator 1 Genmab U.S., Inc. $2,616.32 03/21/2024 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1125193547
Principal investigator 1 ABBVIE INC. $4,233.60 03/15/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708569
Principal investigator 1 ABBVIE INC. $2,462.50 03/15/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708591
Principal investigator 1 ABBVIE INC. $4,233.60 03/15/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100708603
Principal investigator 1 PFIZER INC. $4,642.42 03/14/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076792
Principal investigator 1 PFIZER INC. $975.00 03/11/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131015952
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $60,391.75 03/07/2024 Non-covered Recipient Entity
Start Midwest
PhI/II TIGIT BiSpec combo (Nivo/NG CTLA4) safety & NSCLC expansion - A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer No dispute reported 06/30/2026 1123479980
Principal investigator 1 PFIZER INC. $55,413.75 03/06/2024 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1131104235
Principal investigator 1 PFIZER INC. $8,221.23 03/06/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131104284
Principal investigator 1 PFIZER INC. $13,927.26 03/05/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076107
Principal investigator 1 PFIZER INC. $4,017.55 02/29/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076207
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,295.28 02/27/2024 Non-covered Recipient Entity
CANCER AND HEMATOLOGY
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1110836607
Principal investigator 1 ABBVIE INC. $3,354.75 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704916
Principal investigator 1 ABBVIE INC. $1,776.60 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704918
Principal investigator 1 ABBVIE INC. $3,354.75 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704920
Principal investigator 1 ABBVIE INC. $2,351.70 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704922
Principal investigator 1 ABBVIE INC. $1,544.40 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704924
Principal investigator 1 ABBVIE INC. $4,233.60 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704934
Principal investigator 1 ABBVIE INC. $4,657.50 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704936
Principal investigator 1 ABBVIE INC. $3,354.75 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704940
Principal investigator 1 ABBVIE INC. $1,776.60 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704942
Principal investigator 1 ABBVIE INC. $2,250.45 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704944
Principal investigator 1 ABBVIE INC. $4,657.50 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704946
Principal investigator 1 ABBVIE INC. $2,351.70 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704948
Principal investigator 1 ABBVIE INC. $1,544.40 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704950
Principal investigator 1 ABBVIE INC. $2,250.45 02/26/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704952
Principal investigator 1 ABBVIE INC. $125.35 02/19/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704134
Principal investigator 1 ABBVIE INC. $1,000.00 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704094
Principal investigator 1 ABBVIE INC. $13,000.00 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704096
Principal investigator 1 ABBVIE INC. $1,834.00 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704098
Principal investigator 1 ABBVIE INC. $4,233.60 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704100
Principal investigator 1 ABBVIE INC. $4,233.60 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704102
Principal investigator 1 ABBVIE INC. $3,000.00 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704106
Principal investigator 1 ABBVIE INC. $1,000.00 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704108
Principal investigator 1 ABBVIE INC. $3,355.00 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704110
Principal investigator 1 ABBVIE INC. $1,550.00 02/16/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100704112
Recipient PFIZER INC. $330.00 02/13/2024 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1131083651
Principal investigator 1 PFIZER INC. $975.00 02/12/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131015775
Principal investigator 1 ABBVIE INC. $2,268.00 02/09/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100703588
Principal investigator 1 ABBVIE INC. $2,058.75 02/09/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100703590
Principal investigator 1 ABBVIE INC. $3,500.01 02/09/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100703592
Principal investigator 1 ABBVIE INC. $3,500.01 02/09/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100703594
Principal investigator 1 ABBVIE INC. $2,592.60 02/08/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100703366
Principal investigator 1 ABBVIE INC. $1,613.83 02/08/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100703374
Principal investigator 1 ABBVIE INC. $942.30 02/08/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100703376
Principal investigator 1 PFIZER INC. $22.50 02/07/2024 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131016375
Principal investigator 1 PFIZER INC. $29,559.13 02/06/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076334
Recipient PFIZER INC. $330.00 02/06/2024 Covered Recipient Physician PALBOCICLIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1131083663
Principal investigator 1 PFIZER INC. $13,361.16 02/06/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1131104402
Principal investigator 1 PFIZER INC. $198.45 02/06/2024 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1131104408
Principal investigator 1 MACROGENICS, INC. $8,306.48 02/01/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127668678
Principal investigator 1 MACROGENICS, INC. $3,534.67 02/01/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127668680
Principal investigator 1 MACROGENICS, INC. $5,832.21 02/01/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127668682
Principal investigator 1 PFIZER INC. $126,208.30 02/01/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131076688
Principal investigator 1 PFIZER INC. $72,304.10 01/26/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131110072
Principal investigator 1 MACROGENICS, INC. $2,067.58 01/25/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127668650
Principal investigator 1 MACROGENICS, INC. $879.82 01/25/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127668652
Principal investigator 1 MACROGENICS, INC. $1,451.70 01/25/2024 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1127668654
Principal investigator 1 PFIZER INC. $975.00 01/15/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131017105
Principal investigator 1 Merck Sharp & Dohme LLC $14,200.00 01/09/2024 Non-covered Recipient Entity
SouthTexas Accelerated Rscrch Therapeutics START Midwest
A Phase 1,2 Dose Escalation,Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies No dispute reported 06/30/2026 1136397337
Principal investigator 1 PFIZER INC. $20,955.06 01/09/2024 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131075743
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $65,347.20 01/08/2024 Non-covered Recipient Entity
Start Midwest
Phase I/II TIM3 FIH Monotherapy/Nivo Combination in advanced solid tumors No dispute reported 06/30/2026 1123479976
Principal investigator 1 PFIZER INC. $1,300.00 01/08/2024 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1131017099
Principal investigator 1 ABBVIE INC. $1,613.83 01/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100697353
Principal investigator 1 ABBVIE INC. $1,613.83 01/02/2024 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1100697355